Cowen says Science 37 well positioned for growth, starts coverage
22/10/2021 12:05
** Clinical trial service provider Science 37 SNCE.O is
well positioned for growth and its comprehensive and
decentralized clinical trial platform stands out among
competitors, says Cowen analyst Charles Rhyee
** Cowen starts coverage with "outperform", PT $14
** Says decentralized clinical trials as a concept is
gaining traction in the mainstream as COVID-19 has changed the
way biopharma thinks about drug commercialization
** SNCE's operating system offers a platform that addresses
technological shortcomings in the traditional site-centric
clinical trial model- Rhee
** Adds that the model leads to favorable outcomes in
enrollment speed, participant retention, diverse patient
representation
** Sees a large total addressable market for SNCE of $42.2
billion
** Up to Thursday's close, stock had fallen 2.3% YTD
(Reporting by Dania Nadeem in Bengaluru)